_0_0.png){kind=logo}
Our vision: individualize cancer medicine
COVID-19
This website is intended for a global audience.
Welcome to BioNTechs’s COVID-19 information portal
At BioNTech, we are proud of our contribution to the worldwide efforts to address the global COVID-19 pandemic. Within less than a year we were able to develop our COVID-19 mRNA vaccine following highly scientific and ethical standards.
Our portal provides information around COVID-19, our mRNA technology and Project Lightspeed, our development program for our vaccine against COVID-19. If you are a healthcare professional (HCP), you may access our portal for HCPs which includes scientific background information on SARS-CoV-2 and our vaccine development.
Frequently asked questions
Here we answer questions about our COVID-19 mRNA vaccine und mRNA technology
„We feel a duty to exploit our full technology and Immunotherapy expertise to help address the COVID-19 pandemic emergency. Our aim is clear:
Making a potential vaccine available as quickly as possible – worldwide. “
Prof. Ugur Sahin, M.D., Chief Executive Officer
Our collaborations to accelerate global COVID-19 vaccine development: Pfizer and Fosun
The collaboration with Pfizer is built on the 2018 agreement to jointly develop an mRNA-based influenza vaccine. It aimed to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech’s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine. The collaboration leveraged Pfizer’s broad expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network. During the clinical development stage, BioNTech and its partners provided clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe. BioNTech and Pfizer worked together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic. BioNTech and Pfizer are also working to jointly commercialize the vaccine worldwide (excluding China which is already covered by BioNTech’s collaboration with Fosun Pharma) upon existing regulatory approvals and other potential regulatory approvals.
As part of our strategic collaboration announced in March 2020, BioNTech and Fosun Pharma are jointly conducting clinical trials for our COVID-19 mRNA vaccine in China, leveraging BioNTech’s proprietary mRNA vaccine technology and Fosun Pharma’s clinical development and commercialization capabilities in Greater China market. Fosun Pharma will commercialize the COVID-19 vaccine in Greater China upon regulatory approval, including mainland China, Hong Kong, Macau and Taiwan.
